Tarasi A, Dever L L, Tomasz A
Rockefeller University, New York, NY 10021, USA.
J Antimicrob Chemother. 1997 May;39 Suppl A:121-7. doi: 10.1093/jac/39.suppl_1.121.
We tested the efficacy of quinupristin/dalfopristin, an antibiotic made up of dalfopristin (70%) and quinupristin (30%) against a large panel of Streptococcus pneumoniae strains. The pneumococcal isolates (217) included 200 penicillin-resistant and 17 penicillin-susceptible clinical isolates. Eighty-nine of the 200 resistant bacteria showed an intermediate level and 111/200 showed a high level of resistance to penicillin. Of the highly resistant strains, 56/111 belonged to the multidrug-resistant Spanish/USA epidemic clone of S. pneumoniae, as defined by appropriate genetic techniques. The resistant panel also included six isolates of another multidrug-resistant epidemic clone: isolates with capsular type 6B belonging to the Spanish/Icelandic clone of S. pneumoniae. Quinupristin/dalfopristin had a uniform mean MIC of 0.25 mg/L against all pneumococcal isolates, including 37 strains representing a wide spectrum of erythromycin MICs, from 0.03 up to 8.0 mg/L. Quinupristin/dalfopristin showed powerful bactericidal activity against a penicillin-susceptible test strain in vitro and against representatives of both the Spanish/USA and the Spanish/Icelandic multidrug-resistant clones. The rate of bactericidal activity was independent of drug concentration between 2.5 x and 10 x MIC. Quinupristin/dalfopristin was also tested in a rabbit model of experimental meningitis using 50 mg/kg i.v. bolus injections and a penicillin-susceptible capsular type 3 S. pneumoniae strain as the test organism. Quinupristin/dalfopristin had no effect on the intracisternal growth of bacteria when the drug was injected before CSF inflammation, whereas it caused a 2 log kill in 2 h, after which bacterial growth in the CSF resumed, when injected i.v. at a time of inflammation. When a second dose was given 2 h later, this produced a 3 log loss of viability after 4 h. A single injection of ampicillin 50 mg/kg i.v. caused a similar 3 log kill after 4 h under comparable conditions.
我们测试了由达福普汀(70%)和奎奴普汀(30%)组成的抗生素奎奴普汀/达福普汀对一大组肺炎链球菌菌株的疗效。肺炎球菌分离株(217株)包括200株耐青霉素菌株和17株对青霉素敏感的临床分离株。200株耐药菌中,89株对青霉素呈中度耐药,111株呈高度耐药。在高度耐药菌株中,根据适当的基因技术定义,111株中有56株属于多重耐药的西班牙/美国流行克隆株。耐药组还包括另一个多重耐药流行克隆株的6株分离株:属于肺炎链球菌西班牙/冰岛克隆株的6B型荚膜分离株。奎奴普汀/达福普汀对所有肺炎球菌分离株的平均最低抑菌浓度(MIC)均为0.25mg/L,包括37株代表红霉素MIC范围广泛(从0.03mg/L到8.0mg/L)的菌株。奎奴普汀/达福普汀在体外对一株对青霉素敏感的测试菌株以及西班牙/美国和西班牙/冰岛多重耐药克隆株的代表菌株均表现出强大的杀菌活性。杀菌活性速率在2.5倍至10倍MIC的药物浓度范围内与药物浓度无关。还使用50mg/kg静脉推注在兔实验性脑膜炎模型中测试了奎奴普汀/达福普汀,以一株对青霉素敏感的3型荚膜肺炎链球菌菌株作为测试生物体。当在脑脊液炎症之前注射药物时,奎奴普汀/达福普汀对脑池内细菌生长没有影响,而在炎症时静脉注射,它在2小时内导致细菌数量减少2个对数,之后脑脊液中的细菌生长恢复。当在2小时后给予第二剂时,4小时后细菌活力损失3个对数。在类似条件下,单次静脉注射50mg/kg氨苄西林在4小时后也导致类似的3个对数的细菌数量减少。